Skip to main content

PCVX Vaxcyte, Inc.

Healthcare

63.62

Close 10/16

P/B
3.4
Loading candles…

Is Vaxcyte, Inc. a buy? Fundamentals and valuation first

As of 2026-10-16

Growth: Strong, Momentum: Strong; Valuation: Pricey, Quality: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Pricey.
TTM P/E -8.33 N/A
Price / book 3.43 74th percentile Pricey
Free-cash-flow yield (%) -12.7 23th percentile Average
Quality Weak ROE, TTM is Lagging.
ROE, TTM (%) -38.59 19th percentile Lagging
Operating margin, TTM (%) — N/A
FCF margin, TTM (%) — N/A
Growth Strong Diluted EPS growth, TTM YoY is Top.
Revenue growth, TTM YoY (%) — N/A
Diluted EPS growth, TTM YoY (%) 81.47 82th percentile Top
Momentum Strong All 2 indicators are Top.
60-day return (%) 14.34 86th percentile Top
240-day return (%) 40.5 84th percentile Top
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 239,300,722 94th percentile Top
60-day annualized volatility (%) 78.39 74th percentile Average

Vaxcyte, Inc. (PCVX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Vaxcyte, Inc. to your watchlist to track signal changes on your next visit.

Vaxcyte, Inc. (PCVX) quant signal backtests

Market-wide momentum baseline

Across 98,524 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.48%, a 58.4% positive-return rate, and +3.13 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

More history: Signals not active now

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

12 times historically; 60-day forward avg +7.85%, win rate 40%, beating the market by +4 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

16 times historically; 60-day forward avg +14.37%, win rate 62.5%, beating the market by +11.74 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

6 times historically; 60-day forward avg -9.67%, win rate 33.3%, beating the market by -13.38 pts on average.

Continue researching Vaxcyte, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.